title: Dose-dependent pharmacokinetics of the aldose reductase inhibitor imirestat in man.
abstract: The pharmacokinetics of imirestat were studied in healthy volunteers following single and multiple oral doses. After single doses of 20 to 50 mg, imirestat plasma concentrations declined with an apparent elimination half-life of 50 to 70 hr over the 168 hr in which levels were measured. However, with lower doses (2 to 10 mg), an initial rapid decline in drug concentration was followed by a very slow terminal elimination phase with plasma concentrations decreasing little over the 1 week of sampling. This resulted in a decrease in apparent t 1/2 with increasing dose, from 272 +/- 138 hr at 2 mg to 66 +/- 30 hr at 50 mg. During once-daily dosing of 2 to 20 mg/day for 4 weeks, mean steady-state imirestat concentration appeared to be dose proportional, although the time required to achieve steady state decreased with increasing dose. The mean effective half-life for accumulation ranged from 54 to 98 hr, suggesting that the very slow elimination of drug at low concentrations did not produce disproportionate accumulation of drug at these doses. Mean oral clearance was independent of dose, ranging from 30 to 45 ml/min. At the 2-, 5-, and 20-mg doses, one subject in each group had steady-state concentrations two- to fourfold greater than any of the other five subjects at the same dose, although the reason for this was not apparent from these data. The overall kinetic profile of these data was suggestive of dose-dependent pharmacokinetics resulting from nonlinear tissue binding of imirestat.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Alcon Laboratories, Inc., Fort Worth, Texas 76134.
authors.forename: R K
authors.initials: RK
authors.lastname: Brazzell
authors.forename: P R
authors.initials: PR
authors.lastname: Mayer
authors.forename: R
authors.initials: R
authors.lastname: Dobbs
authors.forename: P J
authors.initials: PJ
authors.lastname: McNamara
authors.forename: R L
authors.initials: RL
authors.lastname: Teng
authors.forename: J T
authors.initials: JT
authors.lastname: Slattery
mesh_terms: D000328:Adult; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D005449:Fluorenes / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006207:Half-Life; D006801:Humans; D006827:Hydantoins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D012044:Regression Analysis; D014018:Tissue Distribution
chemical_list: D005449:Fluorenes; D006827:Hydantoins; C052241:imirestat; D000449:Aldehyde Reductase